Acceptable Intakes for Mutagenic Impurities in Relation to LTL Exposure

Can less than lifetime be applied for nitrosamines?Подробнее

Is the Less Than Lifetime (LTL) Limit applies to NITROSAMINES?Подробнее

Calculating limits for carcinogens: AI, PDE, and less than lifetime as per ICH M7Подробнее

[Multidisciplinary] ICH M7 AddendumПодробнее

Mutagenic Impurities from a Drug Substance Perspective: Highlights from ICH M7 Q&A Draft DocumentПодробнее

How to define limit for mutagenic impurity in drug productПодробнее

ICH M7 - Risk assessment for mutagenic impurities and control strategiesПодробнее

Nitrosamines risk assessment: step 2Подробнее

Risk assessment of potentially mutagenic impurities in drug products approved in BrazilПодробнее

Overview of ICH Guidelines, Less Than Lifetime (LTL) Exposure, and Other Strategies for NitrosaminesПодробнее

Nitrosamine Impurities, NDSRIs and Setting Acceptable Intake (AI) Limits @ToxGyanПодробнее

The purge factor - ICH M7 Option 4Подробнее

Purity is a Virtue: A Practical Guide to the Reporting of ImpuritiesПодробнее

[Multidisciplinary] M7(R2) / Q&As_ENGПодробнее

Why the AI for NDMA is 96ng/day?Подробнее

NITROSAMINE IMPURITIES I RISK ASSESSMENT I CONTROL STRATEGYПодробнее

ICH Q&A Review: Dalia Global and MultiCASEПодробнее

Nitrosamine Impurities-Aug 2023 NDSRIs Limit USFDA Guidance | Control of Nitrosamine Guidance Feb-21Подробнее

Applying Expert Knowledge for ICH M7 Classification - Session 2Подробнее